137864-23-4

Usage

Uses

Used in Hospital Settings:
Ciastatin is used as an adjunct to Imipenem for the treatment of severe bacterial infections, such as urinary tract infections, respiratory tract infections, and intra-abdominal infections. The combination of Cilastatin and Imipenem is particularly beneficial in hospital settings where patients often present with complex and resistant infections.
Used in Cystic Fibrosis Treatment:
Ciastatin may have potential applications in the treatment of cystic fibrosis, a genetic disorder characterized by the production of thick, sticky mucus that leads to chronic lung infections. The combination of Cilastatin and Imipenem could provide a more effective treatment option for managing these infections.
Used in Sepsis Management:
Ciastatin may also have potential applications in the management of sepsis, a life-threatening condition caused by the body's response to infection. The synergistic action of Cilastatin and Imipenem could help combat the severe bacterial infections associated with sepsis, improving patient outcomes.

Upstream product

• 114772-54-2 4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile 
• 137864-24-5 (S)-2-[(2'-cyanobiphenyl-4-ylmethyl)amino]-3-methylbutyric acid benzyl ester hydrochloride 
• 21760-98-5 L-valine benzyl ester 

Downstream Products

• 188240-31-5 (S)-N-(4-Oxo-valeryl)-N-[(2'-cyano-biphenyl-4-yl)methyl]valine benzyl ester 
• 137864-22-3 (S)-2-[(2'-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyric acid benzyl ester 
• 137864-57-4 N-carboethoxy-N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine benzyl ester 
• 188240-32-6 (S)-N-(4-Oxo-valeryl)-N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]valine benzyl ester 
• 188259-69-0 4-Hydroxyvalsartan 
• 188240-33-7 (S)-N-(4-Oxo-valeryl)-N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]valine 

Relevant academic research and scientific papers

PROCESS FOR PREPARATION OF 5-SUBSTITUTED TETRAZOLES

The present invention is a process for preparing sterically hindered 5-substituted tetrazole, which comprises of reacting a nitrile with an organotin halide and an azide in presence of a phase transfer catalyst, in an organic solvent and a co- solvent at reflux temperature for 4 to 20 h.

Process for the Preparation of Valsartan and its Intermediates

The present invention concerns a process for preparing valsartan of Formula I: comprising purifying intermediate benzyl valsartan of Formula IV by crystallizing said benzyl valsartan of lower purity from a first solvent which is a ternary mixture comprising a hydrophilic solvent, a non-polar protic solvent and water; recovering benzyl valsartan from said ternary mixture followed by crystallizing benzyl valsartan from a second solvent comprising a non-polar aprotic solvent or polar aprotic solvent or their mixture; and recovering benzyl valsartan substantially free of organotin impurity; and converting said benzyl valsartan of into valsartan

ACYL COMPOUNDS

Compounds of the formula STR1 in which R 1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X 1 is CO, SO 2, or--O--C(=O)--with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X 2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R. sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O) m--R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO n H 2 where n is 2 or 3; X 3 is a divalent aliphatic hydrocarbon; R 3 is carboxyl, 5-tetrazolyl, SO. sub.3 H, PO. sub.2 H 2, PO 3 H 2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.